» Articles » PMID: 35268423

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Mar 10
PMID 35268423
Authors
Affiliations
Soon will be listed here.
Abstract

Children with acute myeloid leukemia (AML) have a poor prognosis despite the intensification of chemotherapy. Future efforts to improve outcomes should focus on more precise targeting of leukemia cells. CD123, or IL3RA, is expressed on the surface of nearly all pediatric AML samples and is a high-priority target for immunotherapy. The efficacy of an investigational dual-affinity retargeting antibody (DART) molecule (CD123 × CD3; MGD006 or flotetuzumab) was assessed in two distinct patient-derived xenograft (PDX) models of pediatric AML. MGD006 simultaneously binds to CD123 on target cells and CD3 on effector T cells, thereby activating T cells and redirecting them to induce cytotoxicity in target cells. The concurrent treatment of cytarabine and MGD006 was performed to determine the effect of cytarabine on T-cell counts and MGD006 activity. Treatment with MGD006 along with an allogeneic human T-cell infusion to act as effector cells induced durable responses in both PDX models, with CD123 positivity. This effect was sustained in mice treated with a combination of MGD006 and cytarabine in the presence of T cells. MGD006 enhanced T-cell proliferation and decreased the burden of AML blasts in the peripheral blood with or without cytarabine treatment. These data demonstrate the efficacy of MGD006 in prolonging survival in pediatric AML PDX models in the presence of effector T cells and show that the inclusion of cytarabine in the treatment regimen does not interfere with MGD006 activity.

Citing Articles

Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment.

Chomczyk M, Gazzola L, Dash S, Firmanty P, George B, Mohanty V Front Pharmacol. 2024; 15:1409210.

PMID: 39161899 PMC: 11330794. DOI: 10.3389/fphar.2024.1409210.


Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape.

Al-Antary E, Gupte A, Ravindranath Y Indian J Pediatr. 2023; 91(2):176-183.

PMID: 37450248 DOI: 10.1007/s12098-023-04741-3.


Bone Marrow Microenvironment-Induced Chemoprotection in Rearranged Pediatric AML Is Overcome by Azacitidine-Panobinostat Combination.

Lehner K, Gopalakrishnapillai A, Kolb E, Barwe S Cancers (Basel). 2023; 15(12).

PMID: 37370721 PMC: 10296268. DOI: 10.3390/cancers15123112.


CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.

Pelosi E, Castelli G, Testa U Int J Mol Sci. 2023; 24(3).

PMID: 36769040 PMC: 9917129. DOI: 10.3390/ijms24032718.

References
1.
Bras A, de Haas V, van Stigt A, Jongen-Lavrencic M, Beverloo H, Te Marvelde J . CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry B Clin Cytom. 2018; 96(2):134-142. PMC: 6587863. DOI: 10.1002/cyto.b.21745. View

2.
Walter R, Gooley T, van der Velden V, Loken M, van Dongen J, Flowers D . CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007; 109(10):4168-70. PMC: 1885511. DOI: 10.1182/blood-2006-09-047399. View

3.
Tettamanti S, Marin V, Pizzitola I, Magnani C, Giordano Attianese G, Cribioli E . Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013; 161(3):389-401. DOI: 10.1111/bjh.12282. View

4.
Fan D, Li W, Yang Y, Zhang X, Zhang Q, Yan Y . Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells. J Hematol Oncol. 2015; 8:108. PMC: 4596481. DOI: 10.1186/s13045-015-0205-6. View

5.
Gill S, Tasian S, Ruella M, Shestova O, Li Y, Porter D . Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014; 123(15):2343-54. PMC: 3983612. DOI: 10.1182/blood-2013-09-529537. View